PTO/SB/21 (09-04)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Application Number 09/928,048 Filing Date **TRANSMITTAL** August 10, 2001 First Named Inventor **FORM** Thomas L. CANTOR Art Unit 1641 (to be used for all correspondence after initial filing) **Examiner Name** G. Counts Attorney Docket Number Total Number of Pages in This Submission 3 532212001500

L					
	EN	CLOSURES (Check all	that appl	y)	
Fee Transi	mittal Form	Drawing(s)		After Allowance Communication to TC	
Fee Attached		Licensing-related Papers		Appeal Communication to Board of Appeals and Interferences	
Amendment/Reply		Petition		Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)	
After Final		Petition to Convert to a Provisional Application		Proprietary Information	
Affidavits/declaration(s)		Power of Attorney, Revocation Change of Correspondence		Status Letter	
Extension of Time Request		Terminal Disclaimer		Other Enclosure(s) (please Identify below): Statement of Substance of Interview (2 pages)	
Express Abandonment Request		Request for Refund			
Information Disclosure Statement		CD, Number of CD(s)		Return Receipt Postcard	
Certified Copy of Priority Document(s)		Landscape Table on CD			
Reply to Missing Parts/ Incomplete Application		Remarks			
Reply to Missing Parts under 37 CFR 1.52 or 1.53		Customer No. 25225			
<u> </u>					
	SIGNAT	JRE OF APPLICANT, ATTOR	RNEY, OR	AGENT	
Firm Name MORRISON & FOE		RSTER LLP			
Signature	Midal	elsnil			
Printed name	Michael G. Smith				
Date	April 25, 2005		Reg. No.	44,422	

	respondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date
Dated: April 25, 2005	Signature:(Norman Green)

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: April 25, 2005

Signature:

Docket No.: 532212001500

(PATENT)

APR 2 8 2005

OIPE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Thomas L. CANTOR

Application No.: 09/928,048

Filed: August 10, 2001

For: METHODS AND DEVICES FOR DIRECT

DETERMINATION OF CYCLASE

INHIBITING PARATHYROID HORMONE

Confirmation No.: 7860

Art Unit: 1641

Examiner: G. Counts

STATEMENT OF SUBSTANCE OF INTERVIEW

MS Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

This statement is being filed as Applicant is required to file a statement of the substance of a telephonic interview conducted on February 10, 2005 in connection with the above-identified patent application. The interview was conducted between the undersigned and attorney Peng Chen, both representing the applicant, and Examiner Counts.

The telephonic interview was requested by the applicant to allow the applicant to explain that one part of a reference discussed in the response to the office action dated September 10, 2004 had been misinterpreted when the response was prepared. The applicant requested an interview prior to consideration of the response by the Examiner to prevent the applicant's misinterpretation of the reference from influencing the examination, and greatly appreciates that Examiner Counts scheduled the interview after receiving the office action response but before considering it.

The reference, identified as Gao (Clinica Chimica Acta, 245, pg. 39-59 (1996), stated that PTHrp (1-86) was not recognized by a particular antibody; the applicant did not realize when responding to the office action that PTHrp (1-86) differs in amino acid sequence as well as in length from PTH (1-84). Because of this sequence difference, the reference does not fully support one aspect of the applicant's argument offered in the response. During the interview, the applicant explained how the argument is supported by other references of record and offered to provide further supporting information if it would be helpful. The Examiner noted that it might be useful to provide evidence that an antibody discussed in the D'Amour reference, on which the inventor of the subject matter of this application is a co-author, was obtained before the application's filing date.

Examiner Counts agreed to discuss the written description issue with his SPE. In a courtesy phone call a day after the interview, Examiner Counts stated that pursuant to a discussion with a Quality Assurance representative, the arguments and evidence presented were not fully persuasive and that an office action was forthcoming.

In the event the U.S. Patent and Trademark office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to Deposit Account No. 03-1952 referencing docket no. 532212001500. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: April 25, 2005

Respectfully submitted,

Michael G. Smith

Registration No.: 44,422

MORRISON & FOERSTER LLP

3811 Valley Centre Drive, Suite 500 San Diego, California 92130

(858) 720-5113